80 results on '"Selroos, Olof"'
Search Results
2. List of Contributors
3. A Population Management Model of Asthma and Allergy
4. May a different kinetic mode explain the high efficacy/safety profile of inhaled budesonide?
5. Exome Sequencing Identifies Susceptibility Loci for Sarcoidosis Prognosis
6. Differences in Sarcoidosis Around the World
7. Comparison of efficiency of bambuterol and salmeterol
8. SNP Variants in Major Histocompatibility Complex Are Associated with Sarcoidosis Susceptibility—A Joint Analysis in Four European Populations
9. The Finnish experience to save asthma costs by improving care in 1987-2013
10. Budesonide/Formoterol Easyhaler®: Performance Under Simulated Real-Life Conditions
11. Characteristics of reversible and nonreversible COPD and asthma and COPD overlap syndrome patients: an analysis of salbutamol Easyhaler data
12. National and regional asthma programmes in Europe
13. Revisiting early intervention in adult asthma
14. Steroid-Sparing Strategies: Long-Acting Inhaledβ2-Agonists
15. Corticosteroids
16. Diffuse Lung Disease
17. Dry-powder inhalers in acute asthma
18. Inhaler Competence and Patient Satisfaction with Easyhaler®: Results of Two Real-Life Multicentre Studies in Asthma and COPD
19. Major histocompatibility complex class II andBTNL2associations in sarcoidosis: Table 1–
20. Do asthmatic smokers benefit as much as non-smokers on budesonide/formoterol maintenance and reliever therapy? Results of an open label study
21. HLA-DRB1 allele frequencies and C4 copy number variation in Finnish sarcoidosis patients and associations with disease prognosis
22. Continuous versus intermittent inhaled corticosteroid (budesonide) for mild persistent asthma in children—not too much, not too little: Figure 1
23. Is the patient’s baseline inhaled steroid dose a factor for choosing the budesonide/formoterol maintenance and reliever therapy regimen?
24. Bone Mineral Density in Children Treated With Daily or Periodical Inhaled Budesonide: The Helsinki Early Intervention Childhood Asthma Study
25. Skin Thickness in Children Treated With Daily or Periodical Inhaled Budesonide for Mild Persistent Asthma. The Helsinki Early Intervention Childhood Asthma Study
26. Thirteen-year follow-up of early intervention with an inhaled corticosteroid in patients with asthma
27. IMMUNOHISTOCHEMICAL DEMONSTRATION OF LYSOZYME IN THE LYMPH NODES AND KVEIM REACTION PAPULES IN SARCOIDOSIS
28. INFECTIOUS MONONUCLEOSIS WITH THROMBOCYTOPENIC PURPURA
29. Prognostic Significance of Lymphopenia in Sarcoidosis
30. THROMBOCYTOSIS
31. LUPUS-LIKE SYNDROME ASSOCIATED WITH PULMONARY REACTION TO NITROFURANTOIN: Report of Three Cases
32. Sarcoidosis of the Spleen
33. PULMONARY REACTION TO NITROFURANTOIN
34. SARCOIDOSIS AND MYELOMA OF LAMBDA-TYPE IgG
35. Immunological Deficiency in Myelofibrosis
36. IMMUNOGLOBULINS IN PERNICIOUS ANAEMIA
37. Use of dry powder inhalers in acute exacerbations of asthma and COPD
38. Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD A double-blind, randomised, non-inferiority, parallel-group, multicentre study
39. Corrigendum to “Effect of disease duration on dose–response of inhaled budesonide in asthma”
40. Ophthalmologic findings in children with asthma receiving inhaled budesonide
41. Effect of disease duration on dose–response of inhaled budesonide in asthma
42. Do airway clearance mechanisms influence the local and systemic effects of inhaled corticosteroids?
43. A smarter way to manage asthma with a combination of a long-acting ?2-agonist and inhaled corticosteroid
44. Some Aspects on Comparative Efficacy Studies with Inhaled Corticosteroids in Asthma
45. Maintenance plus reliever budesonide/formoterol compared with a higher maintenance dose of budesonide/formoterol plus formoterol as reliever in asthma:an efficacy and cost-effectiveness study
46. Performance of Turbuhaler?? in Patients with Acute Airway Obstruction and COPD, and in Children with Asthma
47. The place of inhaled corticosteroids in chronic obstructive pulmonary disease
48. Once‐Daily Inhaled Budesonide for the Treatment of Asthma: Clinical Evidence and Pharmacokinetic Explanation
49. No Evidence of Glucocorticosteroid-induced Apoptosis of Airway Epithelial CellsIn Vivo
50. Formoterol Turbuhaler® 4.5μg (Delivered Dose) has a Rapid Onset and 12-h Duration of Bronchodilation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.